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Introduction 
The clinical presentation of patients with a non-ST-elevation acute coronary syndrome (NSTEACS) and 
coexisting anemia is a frequent clinical situation. Gastroenterology teams may be reluctant to perform invasive 
endoscopic diagnostic tests or treatments at such an early stage after high risk NSTEACS, and cardiology teams 
may be unwilling to perform invasive investigation and treatment until the etiology of the anemia is better 
understood. It presents a common and complex dilemma for medical teams, and can result in prolonged hospital 
admission and increased patient anxiety; if managed inappropriately it can have an adverse effect on patient 
outcomes. 
Scope of review 
We outline the priorities from cardiology and gastroenterology perspectives, resolve some of the misconceptions, 
and use the evidence available to suggest strategies for optimizing management of these patients. The dual 
presentation of acute active gastrointestinal (GI) blood loss together with an acute coronary syndrome 
(NSTEACS or STEMI [ST elevation myocardial infarction]) is outside the remit of this review but has been 
previously reviewed by our group1. This review covers NSTEACS together with chronic or sub-acute anemia, 
anemia that cannot be accounted for by chronic kidney disease2, heart failure3, or inflammatory disorders. 
Identification of a potential GI etiology of anemia is important as it allows adjustment to both GI and CV 
investigations and treatments that can reduce the likelihood and impact of bleeding 
complications. 
Non-ST-elevation ACS in an expanding group of patients 
In the United States, NSTEACS affects >625,000 patients annually, or three quarters of all patients with acute 
coronary syndrome (ACS)4. In the new ACC/AHA guidelines for management of NSTEACS there is an emphasis 
on an initial approach to care of an ischemia guided strategy replacing a previous conservative management 
approach. However, individualizing care in patients with associated conditions and comorbidities is a critical 
imperative in patients with an ACS and coexisting anemia. 
NSTEACS incidence is rising year on year with negligible changes in mortality and morbidity. The OPERA 
registry5 demonstrated that in-hospital mortality of NSTEACS patients remains high at 4.3% (STEMI 4.6%) and 
at 1 year 11.6% 
(STEMI 9.0%). 
The interaction between anemia and NSTEACS, bleeding and death 
Many risk factors for bleeding (GI sources being a significant proportion) are shared risk factors for increased 
cardiovascular risk in patients who have suffered a NSTEACS (renal impairment, age, diabetes, heart failure). 
These high risk cardiac patients often have potentially most to gain from an invasive treatment strategy but often 
don’t receive invasive 
 
 investigation nor treatment6. A large proportion of NSTEACS patients with high risk scores will have increased 
risk of bleeding. 
The largest study looking at baseline anemia in NSTEACS is that by the OASIS investigators7 who 
retrospectively analyzed 32,170 patients from the OASIS trials. Baseline anemia (WHO criteria) was seen in 
20.5% of patients overall, despite subjects with known malignancy or hemorrhagic diathesis already been 
excluded. Patients were assessed with the GRACE cardiovascular risk score8 and were separated into groups 
according to hemoglobin (Hb) concentration (in 1 g/dL groups from <10 to >17 g/dL). There was a significant 
inverse correlation between GRACE risk score and baseline Hb levels. Patients with the lowest baseline Hb levels 
tended to be older, more frequently females, with lower body weight, higher heart rate, and lower 
systolic/diastolic blood pressure than patients with higher levels. They tended to have more comorbidities as 
shown by the more frequent history of coronary artery disease intervention], or coronary artery bypass grafting 
[CABG]), higher rates of diabetes, hypertension, and heart failure than patients with higher levels of baseline Hb. 
Creatinine clearance tended to be lower in individuals with low baseline Hb levels. Renal anemia should also be 
carefully considered before embarking on coronary angiography and PCI as the addition of contrast induced 
nephropathy in NSTEACS patients has further prognostic implications in addition to the presence of anemia2. 
There was a significant relationship between patients with lower levels of baseline Hb and reduced rates of 
diagnostic coronary angiography (from 62.5% in the normal Hb range down to 38.9% in the group with Hb 
between 10–11 g/dL) and PCI (from 42.9% to 20.5% normal to 10–11 Hb range) during hospitalization. Patients 
with lower Hb tended to receive a lower frequency prescription of beta-blockers and ACE inhibitors. Interestingly 
clopidogrel usage did not significantly differ between the groups but aspirin usage was reduced from 98.2% to 
95.2% in those with the highest and lowest baseline Hb levels respectively. In a progressive manner, as Hb level 
reduces the rate of death (3.3% to 8.9%), death/MI (6.0% to 11.6%), and MI (2.9% to 3.9%) all significantly 
increase (highest to lowest Hb groups in brackets). The overall frequency of major bleeding was 3.3% with an 
increased frequency as the Hb dropped (2.2% to 6.7%). Multiple regression analysis shows that baseline Hb 
together with increasing age, heart failure and creatinine clearance (CrCl) are all independent predictors of 
procedural and nonprocedural bleeding. 
What will the impact of a major bleed have on mortality? 
Major bleeds have a profound effect on the mortality of NSTEACS patients. Manoukian et al., in their analysis 
of the ACUITY trial (n ¼ 13,819)4, found that patients with major bleeding vs. those without had increased 30 
day mortality (7.3% vs. 1.2%, p < 0.0001). Major bleeding was an independent predictor of 30 day mortality (OR 
7.55, 95% CI 4.68 to 
12.18; p < 0.0001), and a stronger independent predictor of mortality than MI (OR 3.96, 95% CI 2.45–6.42; p < 
0.0001). Ischemic events were also higher in the major bleeding group (23.1% vs. 6.8%; p < 0.0001). An increase 
in stent thrombosis in the bleeding group (3.4% vs. 0.6%; p < 0.0001) was also followed by an increase in MI 
and unplanned revascularization. These findings are reinforced in the Eikelboom et al. metaanalysis of the OASIS 
registry9, and the CURE10 trial with ACS patients who were predominantly medically managed with only 10.4% 
having PCI. The association of major bleeding with increased hazard of death in the first 30 days was evident 
even when adjusted for baseline differences and propensity matched (HR 5.37; 95% CI, 3.97–7.26; p < 0.0001). 
Rates of MI and stroke were increased in a similar fashion with one in three of those dying after a major bleed 
having a repeat MI prior to death. 
Gastrointestinal bleeding: the commonest non-access site bleeding source and its impact in NSTEACS 
The commonest cause of non-access site blood loss is secondary to gastrointestinal bleeding (GIB)11. The 
ACUITY trial reported a rate of 4.7% of major bleeding in moderate/high risk ACS patients4. Overall GIB rates 
were 1.3% (48% TIMI major bleeding), this equates to 28.6% of all non-access site major bleeds. This rate of 
  
GIB may be higher as 0.75% of major bleeds with a 4 g/dL reduction in Hb with no overt source of bleeding 
were not formerly defined as GIB. A proportion of these could be non-exteriorized GIB. The ACUITY trial 
highlighted that both minor and major GIB were highly significant in terms of 30 day mortality 9.6% vs. 1.4%, 
composite ischemic outcome 19.8% vs. 7.5%, cardiac death 7.4% vs. 1.2% and MI 12.0% vs. 5.1% (GIB vs. no 
GIB respectively, all p < 0.0001). The impact of GIB was seen out to 1 year for all causes (HR 3.97 2.64–5.99 p 
< 0.0001) and cardiac causes (HR 3.77 2.14–6.63 p < 0.0001) of death together with composite ischemia (HR 
1.90 1.37–2.64 p ¼ 0.0001). The independent predictors for GIB appear similar to those for major bleeding of 
all causes: baseline anemia (OR 2.05 1.42–2.97 p ¼ 0.0001), ST segment deviation >1 mm (OR 1.79 1.12–2.85 
p ¼ 0.015), smoking (OR 1.73 1.14–2.64 p ¼ 0.011), age per 10 years (OR 1.61 1.35–1.92 p < 0.0001), and 
diabetes mellitus (OR 1.46 1.01–2.10 p ¼ 0.044). 
A further adverse sequela from worsening anemia or GI hemorrhage, in the context of ACS, is the need for 
blood transfusion. A meta-analysis of three large clinical trials found that transfusion in the ACS setting increased 
mortality, despite adjustment for other predictive factors12. 
Calculating cardiovascular risk and bleeding risk prior to PCI 
A risk stratified application of an invasive approach (angiography followed by appropriate revascularization) to 
patients with NSTEACS is generally applied in the UK13,14. Moderate/ high risk patients gain short and long term 
benefits including reduced rates of death and MI. Risk scoring is central to applying an invasive approach to 
identify those that will benefit greatest15. The GRACE risk score allows a calculation of in-hospital and 6 month 
outcomes (death/MI)8. A low, intermediate and high GRACE score predicts a <3%, 3–8% and >8% risk of death 
at 6 months respectively8. A more difficult calculation is that of bleeding risk. All the major guidelines for treating 
NSTEACS patients urge special attention to patients with high bleeding risk but few suggest specific instructions 
for calculating bleeding risk. 
Measuring pre-procedural bleeding risk (using only admission clinical variables) the CRUSADE score is the 
most suitable currently available (with a c-statistic of 0.71)16. Based on 71,277 patients and validated with 
117,857 patients it identifies eight independent baseline predictors of in-hospital major bleeding in NSTEACS 
patients (male/female, diabetes, prior vascular disease, heart rate, systolic BP [blood pressure], CCF [congestive 
cardiac failure] signs, baseline HCT [haematocrit] <36% and CrCl). The majority of major bleeding episodes 
(60%) are nonaccess site. In a recent meta-analysis17, bleeding of any type was detrimental to mortality but in 
particular non-access site bleeding (unadjusted 1 year mortality of TIMI [thrombolysis in myocardial infarction] 
major and minor bleeds: no bleed 2.54%, access site 6.16% and non-access site 14.4%). 
How common is low baseline Hb and how can/ should we investigate the NSTEACS patient? 
Not all patients with low baseline Hb have a GI etiology for this. Equally not all patients who develop blood loss 
secondary to GI etiology have low Hb prior to this. Exclusion of other major causes of low Hb needs to be 
identified initially, for example anemia of chronic disease, renal impairment, hematuria, menorrhagia, hemolytic 
anemia, etc. A patient with either low Hb or high bleeding risk should initially have the risks of invasive 
investigation balanced against the benefits. 
Anemia due to chronic blood loss will typically be associated with a low mean cell volume and usually a low 
ferritin level. This type of anemia is termed iron deficiency anemia (IDA) and in the vast majority the source of 
bleeding will be in the gastrointestinal tract. Its prevalence in adult males and post-menopausal females is 2–
5%18. Not all cases of IDA are due to bleeding, malabsorption and blood dyscrasias such as myeloma can also 
present in this fashion and require hematological input and investigation (Table 1)19. 
A focused history for excluding other causes of anemia, as above, is important. Ferritin and iron binding studies 
may assist with overt markers of iron deficiency but these may not be present if anemia is of recent onset 
following use of dual antiplatelet drugs and anticoagulants. Ferritin is an acute phase reactant and may be elevated 
 in the presence of concurrent inflammation and mask iron deficiency in certain individuals. If iron deficiency is 
confirmed then all patients should have serology checked to exclude celiac disease. 
Investigating the GI tract usually involves performing gastroscopy (with duodenal biopsy) and colonoscopy; 
the latter may be deemed unsuitable if the patient has significant comorbidity. Computed tomographic 
colonography (CTC) (or barium enema if unavailable) is a suitable alternative, and also indicated if colonoscopy 
is attempted but not completed to the cecum. 
 
Table 1. Causes of iron deficiency anemia with prevalence as percentage of total. 
 
Occult GI Blood Loss  
Common:  
Aspirin/NSAID use 10–15% 
Colonic carcinoma 5–10% 
Gastric carcinoma 5% 
Benign gastric ulceration 5% 
Angiodysplasia 5% 
 
Uncommon: 
Esophagitis 2–4% 
Esophageal carcinoma 1–2% 
Gastric antral vascular ectasia 1–2% 
Small bowel tumors 1–2% 
Ampullary carcinoma <1% 
Ancylomasta duodenale <1% 
Malabsorption 
Common:  
Celiac disease 4–6% 
Gastrectomy <5% 
H. pylori colonization <5% 
Uncommon:  
Gut resection <1% 
Bacterial overgrowth <1% 
Non-GI Blood Loss  
Common: 
Menstruation 20–30% 
Blood donation 5% Uncommon: Hematuria 1% 
Epistaxis <1% 
Myeloma <1% 
 
Table taken from BSG Guidelines for Management of Iron Deficiency Anemia21. 
Small bowel examination can be achieved using video capsule endoscopy/enteroscopy; it is not routinely 
recommended unless there are symptoms to suggest small bowel pathology or Hb levels cannot be maintained 
with iron therapy20. The overall diagnostic yield for investigating IDA ranges from 49% to 75%22,23. 
Risk of upper GI endoscopy in NSTEACS 
It remains common clinical practice to postpone endoscopy until at least 6 weeks after NSTEACS to ‘‘enable the 
cardiac condition to stabilise’’. This area has scant evidence to support what are arbitrary time cut-offs. The 6 
week interval is concordant with surgical practice of delaying elective noncardiac surgery after myocardial 
infarction (MI)24. Whilst the function of these delays is to try and address the risk of investigation (GI) vs. 
potential benefit it remains questionable to globally apply these protocols in light of the limited evidence 
available. 
  
A case–control study of 200 patients who underwent gastroscopy within 30 days of a MI found that 7.5% had 
complications vs. 1.5% of controls (p < 0.007); two of these complications were severe25. The indication for 
OGD [Oesophagogastroduodenoscopy] in the majority of cases was acute GI bleeding (65%) and MI was defined 
as any CK [Creatinine Kinase] level >225 U/L and a CK-MB [Creatinine Kinase Muscle bound] fraction >5%. 
This 1999 analysis was prior to the widespread use of thienopyridines and using MI definitions, which included 
mostly STEMI patients with larger MIs. The two severe complications included a fatal ventricular tachycardia 
and near respiratory arrest requiring intubation. 
The 13 mild complications included 11 episodes of transient hypotension and two of transient hypoxia. Control 
group complications were all mild. 
Another study of 85 patients who underwent gastroscopy within 28 days of MI had a complication rate of 8%. 
All of these were mild (transient hypotension, hypoxia or bradycardia) with no procedure related mortality26. A 
retrospective study of a variety of endoscopic procedures performed within 30 days of MI analyzed the safety of 
the specific timing of endoscopy (number of days post-MI), and with respect to the severity of cardiac damage21. 
In 135 patients, major complications occurred in 1.5%; episodes occurred when endoscopy was performed on the 
same day as MI. The severity of MI (according to presence of STEMI, left ventricular impairment, and troponin 
peak) had no significant effect. 
In a prospective study of emergency gastroscopy performed for upper GI bleeding in 50 patients with no 
coronary artery disease (CAD) compared to 50 with CAD there was a higher incidence of ventricular arrhythmia, 
and silent ischemia in those with known CAD, although most were subclinical. The only in-hospital cardiac death 
was a patient in the CAD group with three vessel disease who developed angina 5 days after gastroscopy and 
died of ventricular fibrillation, arguably unrelated to the gastroscopy21. ECG monitoring of patients with stable 
angina undergoing gastroscopy has showed evidence of silent ischemia in 42% of patients. The main risk factor 
appeared to be the presence of tachycardia, and so the use of b-blockers and Ivabradine was recommended with 
Buscopan avoidance27. 
Risk of lower GI endoscopy in NSTEACS 
Data on performing colonoscopy in NSTEACS is sparse. Colonoscopy is regarded as being more physiologically 
demanding than upper GI endoscopy in part because of electrolyte and fluid shifts secondary to bowel 
preparations resulting in hypotension but also vagal nerve stimulation due to mesenteric stretch and air 
insufflation. These complications can be reduced with optimal colonoscopy technique. In a case–control study 
100 patients had colonoscopy within 30 days of MI. The complication rate (9%) was significantly higher than 
controls (1%), (p < 0.03)28. Complications were mostly non-significant minor ones such as transient hypotension 
and bradycardia, with one major complication involving death of a patient 14 hours after colonoscopy (thought 
unlikely to be related to the procedure). Colonoscopy completion rate was 85% in study patients vs. 93% in 
controls. 
Another study of patients undergoing elective colonoscopy indicated more cardiac arrhythmias in patients with 
stable angina29. Importantly this did not equate to any clinical features at the time of the procedure. Two deaths 
occurred in the study, both in the Ischaemic heart disease (IHD) group (4.6% 30 day mortality in this group). 
Flexible sigmoidoscopy was considered to be safe within 30 days of MI, complications rare (2.6%) and minor30. 
Risk of endoscopic GI investigations: in summary 
The studies outlined for both endoscopic modalities are limited by size, case selection and measurement bias, 
their retrospective nature and lack of applicability to NSTEACS patients where overall size of MI is often smaller 
is questionable. In the context of NSTEACS patients with moderate, high and highest GRACE risk (mortality 
risk: 3–6%, >6–9% and >9% at 6 months respectively) this data suggests that a proportion of these patients may 
benefit from tailored cardiovascular and GI investigation despite their anemia when balanced against the risk of 
 investigating it acutely. Further large scale prospective studies are required in NSTEACS patients undergoing GI 
investigation and treatment for contemporary safety data. 
Alternative modes of investigation 
Radiological investigation of the upper GI tract is of limited value and is not recommended in the BSG guidelines 
for iron deficiency anemia management. Barium meals and CT scans can only detect large structural 
abnormalities and are considered to be inferior to an OGD to visualize the upper GI tract. 
Radiological imaging offers a less invasive approach for investigating the lower GI tract and may have benefits 
in the setting of NSTEACS. Furthermore colonoscopy will not reach the cecum in 8% of cases, thereby failing 
to exclude proximal colonic pathology31. CTC is superior to barium enema (BE) in detecting colorectal cancer 
and large colonic polyps, and has a similar sensitivity to colonoscopy32,33. A meta-analysis showed that for polyps 
>1 cm, BE had a sensitivity of 48% and specificity of 90%, whilst CTC’s sensitivity was 81% and specificity 
96%34. Both techniques can be limited by the need for a full bowel preparation. 
An alternative radiological investigation which does not involve bowel preparation or air insufflation is 
minimal preparation CT. This uses oral and intravenous contrast and has been used in frail patients in whom more 
invasive tests are considered inappropriate. Although not effective at detecting small polyp lesions, it does have 
sensitivity for detecting colorectal cancers (sensitivity of 83% and specificity of 90%)35. In the context of 
NSTEACS the detection of colorectal cancer rather than small polyps is of greater significance, and so this less 
invasive investigation is useful. In obscure GI bleeding capsule endoscopy has a diagnostic yield of 63%36. If it 
becomes more widely accepted it could be a valuable tool for investigating IDA in the setting of NSTEACS. 
Performing both cardiac and GI investigations: revascularization strategies directed by GI pathology 
Performing coronary angiography allows anatomic risk stratification delineating minor, moderate or major 
coronary disease and allows further evaluation of high risk appearances such as thrombus burden/ulcerated 
plaque morphology, etc. These appearances can dictate and potentially predict future cardiac events. 
 
The angiographic appearances also dictate the mode of revascularization required such as coronary artery bypass 
grafting (CABG) or PCI. Peri-procedural adjunctive pharmacotherapy can be adjusted towards a lower bleeding 
risk strategy by reduction in the use of glycoprotein II/IIIa inhibitors in 
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Figure 1. Anemia and non-ST-elevation ACS – double jeopardy. Suggested decision making tree. 
 those with high risk features. Antiplatelet therapies can also be modified away from more potent drugs (ticagrelor 
and prasugrel) depending on the GI pathology found. PCI treatments can also be modified, such as balloon only 
angioplasty, bare metal and drug eluting stent implantation to decreased long term bleeding risk due to dual 
antiplatelet treatment duration. Knowledge of incipient GI pathology also has clear treatment ramifications for 
CABG as the presence of pre-existing gastric or duodenal ulceration being exacerbated by heparinization and/or 
stress ulceration induced at surgery could materially affect outcome. 
This approach (outlined in Figure 1) of diagnostic coronary angiography initially followed by GI investigations 
allows a crucial better informed synthesis of decision making based upon the two concurrent clinical risks posed 
to the patient by two distinct clinical pathologies: an acute coronary syndrome and underlying anemia of uncertain 
etiology. Ultimately the best possible knowledge of both pathological processes allows ‘‘optimal’’ decision 
making and thus the most appropriate guided therapy or therapies. 
Conclusion 
Patients presenting with an acute coronary syndrome and concomitant anemia or blood loss once they have 
commenced powerful antithrombotic therapy are currently inadequately risk stratified and treated. This review 
highlights the patients’ high risk profile from a cardiac and gastroenterological perspective. The schematic 
presented offers a clear pragmatic clinical pathway of cardiac and GI risk stratification measures readily available 
on admission, variables which can enable clinicians to prioritize investigations to minimize both investigational 
and treatment delays and enact the most appropriate therapies based upon the distinct pathologies present. 
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